Although most of our regimens targeting myofibroblastic PSC for pancreatic cancer (including depletion of a-SMA + PSC and blockade of Shh) have failed, we have still achieved some successes such as blocking TGF-β or inducing PSC quiescence. This evidence concerns the gene SHH and pancreatic neoplasm.